Cat. No.: HY-L022P

FDA-Approved Drug Library Plus

96 Cited Publications

Customer Review

Based on 96 publication(s) in Google Scholar

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,666 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

PDF
Excel
SDF
Manual

Size

Price

Stock

Quantity

In-stock

(2-3 weeks)

Get a Quotation Now

In-stock

(2-3 weeks)

Get a Quotation Now

(2-3 weeks)

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Description & Advantages
Product Details
- Formulation
- Layout
- Container
- Storage
- Shipping
Publications (96)
Documentation
Composition

Description & Advantages

• A unique collection of 3,666 approved drugs for high throughput screening (HTS) and high content screening (HCS).

• Used in the research of oncology, cardiology, anti-inflammatory, immunology, dermatology, endocrinology, neurology, and more.

• A useful tool for researching new targets of marketed old drugs.

• All compounds have been approved by the FDA, EMA and other countries.

• Structurally diverse, bioactive, and cell permeable.

• More detailed compound information with structure, IC₅₀, and brief introduction.

• NMR and HPLC validated ensure high purity.

• All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 3,666 marketed drugs supplied as pre-dissolved Solutions or Solid

Solution: 3,142 compounds supplied in 10 mM solution, 65 compounds supplied in 2 mM solution, 29 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage

-80°C

Shipping

Blue ice or dry ice